Leerink Partners Boosts KalVista Pharmaceuticals (NASDAQ:KALV) Price Target to $20.00

KalVista Pharmaceuticals (NASDAQ:KALV - Free Report) had its price target lifted by Leerink Partners from $18.00 to $20.00 in a research note published on Monday,Benzinga reports. Leerink Partners currently has an outperform rating on the specialty pharmaceutical company's stock.

Other equities research analysts have also recently issued reports about the company. Needham & Company LLC reiterated a "buy" rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. Finally, Jones Trading reaffirmed a "buy" rating and issued a $30.00 price objective on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $26.29.

KalVista Pharmaceuticals Stock Performance

Shares of KALV stock traded down $0.48 during mid-day trading on Monday, reaching $15.51. 1,981,962 shares of the company were exchanged, compared to its average volume of 745,916. KalVista Pharmaceuticals has a fifty-two week low of $7.30 and a fifty-two week high of $16.32. The company has a market capitalization of $771.16 million, a P/E ratio of -4.17 and a beta of -0.04. The business's 50 day simple moving average is $12.51 and its 200 day simple moving average is $11.14.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last released its quarterly earnings results on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($2.86). During the same period last year, the business earned ($1.07) EPS. On average, analysts forecast that KalVista Pharmaceuticals will post -3.56 EPS for the current year.

Insider Transactions at KalVista Pharmaceuticals

In related news, CEO Benjamin L. Palleiko sold 7,169 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $14.50, for a total transaction of $103,950.50. Following the transaction, the chief executive officer directly owned 315,074 shares of the company's stock, valued at $4,568,573. The trade was a 2.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Paul K. Audhya sold 2,776 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, May 19th. The stock was sold at an average price of $11.84, for a total value of $32,867.84. Following the completion of the transaction, the insider directly owned 106,611 shares in the company, valued at $1,262,274.24. This represents a 2.54% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 15,899 shares of company stock worth $206,176. 10.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. Suvretta Capital Management LLC lifted its holdings in KalVista Pharmaceuticals by 16.6% in the 4th quarter. Suvretta Capital Management LLC now owns 4,913,012 shares of the specialty pharmaceutical company's stock worth $41,613,000 after purchasing an additional 701,007 shares during the last quarter. Tang Capital Management LLC increased its position in shares of KalVista Pharmaceuticals by 13.2% during the fourth quarter. Tang Capital Management LLC now owns 4,893,847 shares of the specialty pharmaceutical company's stock valued at $41,451,000 after purchasing an additional 572,300 shares during the period. Frazier Life Sciences Management L.P. increased its position in shares of KalVista Pharmaceuticals by 32.5% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company's stock valued at $41,400,000 after purchasing an additional 1,200,000 shares during the period. Vestal Point Capital LP increased its position in shares of KalVista Pharmaceuticals by 19.3% during the fourth quarter. Vestal Point Capital LP now owns 4,770,000 shares of the specialty pharmaceutical company's stock valued at $40,402,000 after purchasing an additional 770,000 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of KalVista Pharmaceuticals by 1.9% during the first quarter. Vanguard Group Inc. now owns 2,298,598 shares of the specialty pharmaceutical company's stock valued at $26,526,000 after purchasing an additional 43,355 shares during the period.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).